Status:
COMPLETED
A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Brief Summary
The purpose of the study is to evaluate the outcome of treatment switch defined as an improvement in CGI-CB scale (Clinical Global Impression - Clinical Benefit).
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia (as per DSM-IV), at least 6 months prior to enrolment in the study
- Subjects who have initiated a new antipsychotic treatment within the preceding 2 weeks
- Subjects whose prior and current antipsychotic treatment consists of any typical or atypical antipsychotic monotherapy
Exclusion
- Subjects fulfilling criteria for diagnosis of any other psychiatric condition (except from schizophrenia), as per DSM-IV Axis Ι, concomitant organic mental disorder or mental retardation
- Substance abuse or dependence (with the exception of nicotine dependence), as defined by DSM-IV criteria and not in full remission
- Female subjects who are pregnant or lactating
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
574 Patients enrolled
Trial Details
Trial ID
NCT00999895
Start Date
October 1 2009
End Date
September 1 2010
Last Update
February 1 2011
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Pátrai, Achaias, Greece
2
Research Site
Nafplion, Argolidas, Greece
3
Research Site
Tripoli, Arkadias, Greece
4
Research Site
Athens, Attica, Greece